Update on the reciprocal interference between immunosuppressive therapy and gut microbiota after kidney transplantation

Maurizio Salvadori, G. Rosso
{"title":"Update on the reciprocal interference between immunosuppressive therapy and gut microbiota after kidney transplantation","authors":"Maurizio Salvadori, G. Rosso","doi":"10.5500/wjt.v14.i1.90194","DOIUrl":null,"url":null,"abstract":"Gut microbiota is often modified after kidney transplantation. This principally happens in the first period after transplantation. Antibiotics and, most of all, immunosuppressive drugs are the main responsible. The relationship between immunosuppressive drugs and the gut microbiota is bilateral. From one side immunosuppressive drugs modify the gut microbiota, often generating dysbiosis; from the other side microbiota may interfere with the immunosuppressant pharmacokinetics, producing products more or less active with respect to the original drug. These phenomena have influence over the graft outcomes and clinical consequences as rejections, infections, diarrhea may be caused by the dysbiotic condition. Corticosteroids, calcineurin inhibitors such as tacrolimus and cyclosporine, mycophenolate mofetil and mTOR inhibitors are the immunosuppressive drugs whose effect on the gut microbiota is better known. In contrast is well known how the gut microbiota may interfere with glucocorticoids, which may be transformed into androgens. Tacrolimus may be transformed by microbiota into a product called M1 that is 15-fold less active with respect to tacrolimus. The pro-drug mycophenolate mofetil is normally transformed in mycophenolic acid that according the presence or not of microbes producing the enzyme glucuronidase, may be transformed into the inactive product.","PeriodicalId":506536,"journal":{"name":"World Journal of Transplantation","volume":"21 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5500/wjt.v14.i1.90194","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Gut microbiota is often modified after kidney transplantation. This principally happens in the first period after transplantation. Antibiotics and, most of all, immunosuppressive drugs are the main responsible. The relationship between immunosuppressive drugs and the gut microbiota is bilateral. From one side immunosuppressive drugs modify the gut microbiota, often generating dysbiosis; from the other side microbiota may interfere with the immunosuppressant pharmacokinetics, producing products more or less active with respect to the original drug. These phenomena have influence over the graft outcomes and clinical consequences as rejections, infections, diarrhea may be caused by the dysbiotic condition. Corticosteroids, calcineurin inhibitors such as tacrolimus and cyclosporine, mycophenolate mofetil and mTOR inhibitors are the immunosuppressive drugs whose effect on the gut microbiota is better known. In contrast is well known how the gut microbiota may interfere with glucocorticoids, which may be transformed into androgens. Tacrolimus may be transformed by microbiota into a product called M1 that is 15-fold less active with respect to tacrolimus. The pro-drug mycophenolate mofetil is normally transformed in mycophenolic acid that according the presence or not of microbes producing the enzyme glucuronidase, may be transformed into the inactive product.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肾移植后免疫抑制疗法与肠道微生物群相互干扰的最新进展
肾移植后,肠道微生物群通常会发生变化。这主要发生在移植后的第一阶段。抗生素和最主要的免疫抑制剂是主要原因。免疫抑制药物与肠道微生物群之间的关系是双边的。一方面,免疫抑制剂会改变肠道微生物群,往往会造成菌群失调;另一方面,微生物群可能会干扰免疫抑制剂的药代动力学,产生比原药物活性更强或更弱的产物。这些现象会对移植结果和临床后果产生影响,因为排斥、感染、腹泻可能是由菌群失调引起的。皮质类固醇、钙神经蛋白抑制剂(如他克莫司和环孢素)、霉酚酸酯和 mTOR 抑制剂等免疫抑制剂对肠道微生物群的影响是众所周知的。相反,众所周知,肠道微生物群可能会干扰糖皮质激素,而糖皮质激素可能会转化为雄激素。他克莫司可被微生物群转化为一种名为 M1 的产物,其活性比他克莫司低 15 倍。原药霉酚酸酯(mycophenolate mofetil)通常会转化为霉酚酸,根据是否存在产生葡萄糖醛酸酶的微生物,霉酚酸酯可能会转化为非活性产物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Critical considerations for the management of acute abdomen in transplant patients Frequency of and reasons behind non-listing in adult patients referred for liver transplantation: Results from a retrospective study Impact of payment source, referral site, and place of residence on outcomes after allogeneic transplantation in Mexico Incidence, risk factors and clinical outcome of multidrug-resistant organisms after heart transplantation Whole-eye transplantation: Current challenges and future perspectives
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1